Shikonin Induces Glioma Necroptosis, Stemness Decline, and Impedes (Immuno)Proteasome Activity
Gliomas, the most prevalent primary intracranial tumors, exhibit notable features such as heightened malignancy, rapid recurrence, and elevated mortality rates. Presently, standard therapeutic approaches yield limited curative outcomes. Shikonin, an extract derived from traditional Chinese medicine,...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2024/1348269 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832559535955378176 |
|---|---|
| author | Xianyun Qin Lu Zhang Jilan Liu Yan Lu Fuyao Zhou Feng Jin |
| author_facet | Xianyun Qin Lu Zhang Jilan Liu Yan Lu Fuyao Zhou Feng Jin |
| author_sort | Xianyun Qin |
| collection | DOAJ |
| description | Gliomas, the most prevalent primary intracranial tumors, exhibit notable features such as heightened malignancy, rapid recurrence, and elevated mortality rates. Presently, standard therapeutic approaches yield limited curative outcomes. Shikonin, an extract derived from traditional Chinese medicine, demonstrates notable bioactivity against various tumors, including gliomas. This study elucidates Shikonin’s capacity to effectively induce necroptosis in glioma cells, concurrently mitigating glioma stemness, as evidenced by diminished levels of stem cell markers, namely SOX2, CD44, CHI3L1, and CD24. Our findings indicate that Shikonin-induced programed necrosis leads to a downregulation of proteasome activity and a decrease in the expression of immune proteasome subunits PSMB8/9/10 and PSME1/2/3, contributing to the attenuation of stemness in gliomas. This study comprehensively investigates the interplay between (immuno)proteasome dynamics, Shikonin-mediated necroptosis, and the consequential reduction in glioma stemness, both in vitro and in vivo. The discussion extends to the potential of Shikonin as a promising therapeutic agent in the management of gliomas, offering a novel avenue for drug development in this challenging clinical context. |
| format | Article |
| id | doaj-art-0db002a97fe34fecbb344b8769e6507a |
| institution | Kabale University |
| issn | 1687-9678 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-0db002a97fe34fecbb344b8769e6507a2025-02-03T01:29:49ZengWileyStem Cells International1687-96782024-01-01202410.1155/2024/1348269Shikonin Induces Glioma Necroptosis, Stemness Decline, and Impedes (Immuno)Proteasome ActivityXianyun Qin0Lu Zhang1Jilan Liu2Yan Lu3Fuyao Zhou4Feng Jin5Medical Research CenterDepartment of NeurosurgeryMedical Research CenterClinical Laboratory Medicine DepartmentDepartment of NeurosurgeryDepartment of NeurosurgeryGliomas, the most prevalent primary intracranial tumors, exhibit notable features such as heightened malignancy, rapid recurrence, and elevated mortality rates. Presently, standard therapeutic approaches yield limited curative outcomes. Shikonin, an extract derived from traditional Chinese medicine, demonstrates notable bioactivity against various tumors, including gliomas. This study elucidates Shikonin’s capacity to effectively induce necroptosis in glioma cells, concurrently mitigating glioma stemness, as evidenced by diminished levels of stem cell markers, namely SOX2, CD44, CHI3L1, and CD24. Our findings indicate that Shikonin-induced programed necrosis leads to a downregulation of proteasome activity and a decrease in the expression of immune proteasome subunits PSMB8/9/10 and PSME1/2/3, contributing to the attenuation of stemness in gliomas. This study comprehensively investigates the interplay between (immuno)proteasome dynamics, Shikonin-mediated necroptosis, and the consequential reduction in glioma stemness, both in vitro and in vivo. The discussion extends to the potential of Shikonin as a promising therapeutic agent in the management of gliomas, offering a novel avenue for drug development in this challenging clinical context.http://dx.doi.org/10.1155/2024/1348269 |
| spellingShingle | Xianyun Qin Lu Zhang Jilan Liu Yan Lu Fuyao Zhou Feng Jin Shikonin Induces Glioma Necroptosis, Stemness Decline, and Impedes (Immuno)Proteasome Activity Stem Cells International |
| title | Shikonin Induces Glioma Necroptosis, Stemness Decline, and Impedes (Immuno)Proteasome Activity |
| title_full | Shikonin Induces Glioma Necroptosis, Stemness Decline, and Impedes (Immuno)Proteasome Activity |
| title_fullStr | Shikonin Induces Glioma Necroptosis, Stemness Decline, and Impedes (Immuno)Proteasome Activity |
| title_full_unstemmed | Shikonin Induces Glioma Necroptosis, Stemness Decline, and Impedes (Immuno)Proteasome Activity |
| title_short | Shikonin Induces Glioma Necroptosis, Stemness Decline, and Impedes (Immuno)Proteasome Activity |
| title_sort | shikonin induces glioma necroptosis stemness decline and impedes immuno proteasome activity |
| url | http://dx.doi.org/10.1155/2024/1348269 |
| work_keys_str_mv | AT xianyunqin shikonininducesgliomanecroptosisstemnessdeclineandimpedesimmunoproteasomeactivity AT luzhang shikonininducesgliomanecroptosisstemnessdeclineandimpedesimmunoproteasomeactivity AT jilanliu shikonininducesgliomanecroptosisstemnessdeclineandimpedesimmunoproteasomeactivity AT yanlu shikonininducesgliomanecroptosisstemnessdeclineandimpedesimmunoproteasomeactivity AT fuyaozhou shikonininducesgliomanecroptosisstemnessdeclineandimpedesimmunoproteasomeactivity AT fengjin shikonininducesgliomanecroptosisstemnessdeclineandimpedesimmunoproteasomeactivity |